• Context Therapeutics amended its exclusive license agreement with BioAtla for CT-202, eliminating all future milestone and royalty obligations.
• The amendment requires a USD 4.5 million upfront payment, with a final USD 2 million payment due by Aug. 1, 2026, in exchange for a fully paid-up, non-terminable license.
• Phase 1 initiation for the CT-202 trial is expected in Q3 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Context Therapeutics Inc. published the original content used to generate this news brief on May 18, 2026, and is solely responsible for the information contained therein.